General
Preferred name
STAVUDINE
Synonyms
2',3'-didehydro-3'-deoxythymidine ()
Stavudine (sodium) ()
d4T sodium ()
d4T ()
BMY-27857, Sanilvudine, NSC 163661,d4T ()
Stavudine sodium ()
Stavudine (d4T) ()
Stavudinum ()
Sanilvudine ()
D-4T ()
NSC-759897 ()
Stavudine (dt4) ()
Estavudina ()
Zerit Xr ()
NSC-163661 ()
Zerit ()
BMY-27857 ()
Stavudine-13C-d3 ()
P&D ID
PD001676
CAS
3056-17-5
132425-31-1
134624-73-0
2750534-86-0
Tags
available
prodrug
drug
Approved by
FDA
First approval
1994
Drug indication
Human immunodeficiency virus infection
AIDS
Drug Status
approved
withdrawn
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Stavudine is a nucleoside reverse transcriptase inhibitors (NRTI) class antiretriviral agent. It is a thymidine analogue.
(GtoPdb)
DESCRIPTION
Stavudine (d4T) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Stavudine has activity against HIV-1 and HIV-2. Stavudine also inhibits the replication of mitochondrial DNA (mtDNA). Stavudine reduces NLRP3 inflammasome activation and modulates Amyloid-¦Â autophagy. Stavudine induces apoptosis[1][2][3][4].
DESCRIPTION
Naturally occuring flavonoid and antioxidant; neuroprotective
(Tocris Bioactive Compound Library)
DESCRIPTION
Nucleoside analog; antiviral
(Tocriscreen Plus)
DESCRIPTION
Nucleoside analog; inhibits HIV replication in vitro
(LOPAC library)
DESCRIPTION
Stavudine iis a nucleoside analog reverse transcriptase inhibitor (NARTI) active against HIV.
(Enamine Bioactive Compounds)
DESCRIPTION
Stavudine sodium is a dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. Stavudine sodium is an analog of thymidine. It is phosphorylated by cellular kinases into active triphosphate. Stavudine sodium triphosphate inhibits the HIV reverse transcriptase by competing with natural substrate, thymidine triphosphate. It also causes termination of DNA synthesis by incorporating into it.
Mice were treated for 2 weeks with stavudine d4T (500 mg/kg/day), L-carnitine (200 mg/kg/day) or both drugs concomitantly. Body fatness was assessed by dual energy X-ray absorptiometry, and investigations were performed in plasma, liver, muscle and WAT. D4T reduced the gain of body adiposity, WAT leptin, whole body FAO and plasma ketone bodies, and increased liver triglycerides and plasma aminotransferases with mild ultrastructural abnormalities in hepatocytes. (BOC Sciences Bioactive Compounds)
Mice were treated for 2 weeks with stavudine d4T (500 mg/kg/day), L-carnitine (200 mg/kg/day) or both drugs concomitantly. Body fatness was assessed by dual energy X-ray absorptiometry, and investigations were performed in plasma, liver, muscle and WAT. D4T reduced the gain of body adiposity, WAT leptin, whole body FAO and plasma ketone bodies, and increased liver triglycerides and plasma aminotransferases with mild ultrastructural abnormalities in hepatocytes. (BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
10
Organisms
5
Compound Sets
27
Axon Medchem Screening Library
BOC Sciences Bioactive Compounds
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LOPAC library
MedChem Express Bioactive Compound Library
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
The Spectrum Collection
Tocris Bioactive Compound Library
Tocriscreen Plus
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
58
Molecular Weight
224.08
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
2
Rotatable Bonds
2
Ring Count
2
Aromatic Ring Count
1
cLogP
-0.71
TPSA
84.32
Fraction CSP3
0.4
Chiral centers
2.0
Largest ring
6.0
QED
0.65
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Other Pharmacology
Selectivity
Reverse Transcriptase
Target
HIV
NRT inhibitor
Apoptosis
Autophagy
NOD-like Receptor (NLR)
Nucleoside antimetabolite/analog
Pathway
Anti-infection
Cell Cycle/DNA Damage
Immunology/Inflammation
Primary Target
Antivirals
Indication
human immunodeficiency virus (HIV-1)
MOA
DNA directed DNA polymerase inhibitor, nucleoside reverse transcriptase inhibitor
Therapeutic Class
Anti-HIV Agents
Solubility
In vitro:<br/>10 mM in DMSO
Source data
